68Ga-XMFH01 PET/Fluorescence Imaging in Prostate Cancer

Korábbi kezelés

• Patients who have previously received any of the following treatments for prostate cancer: (a) Systemic therapy: More than 2 months of androgen deprivation therapy (ADT) or conventional hormonal therapy, or any prior treatment with novel hormonal agents, chemotherapy, immunotherapy, or targeted therapy. (b) Local therapy: Prior pelvic radiotherapy or surgery for prostate cancer;

Más betegség

• Patients who are medically unfit for or unable to tolerate the planned surgical procedure for prostate cancer.

Egyéb

• Patients who are unwilling or unable to provide written informed consent or cooperate with study procedures;
• Patients who are unable to tolerate PET/CT examinations;

• Patients diagnosed with prostate cancer who are scheduled to undergo surgical treatment;
• Adult patients (aged 18 years or older);
• No evidence of distant metastases (M0), including nonregional lymph node metastases, bone metastases, or visceral metastases, as determined by conventional imaging (bone scintigraphy, CT, or MRI) or PET/CT;
• Patients with regional pelvic lymph node metastases (N1) are eligible for inclusion;
• Patients who have been fully informed of their disease status, treatment options, and study procedures, and who voluntarily provide written informed consent;
• Patients who are willing and able to comply with the study protocol, including scheduled visits, treatment procedures, and required laboratory and imaging examinations.